老年人用药风险管理原则和措施

doi:10.19803/j.1672-8629.20220585

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (9): 1031-1034.
DOI: 10.19803/j.1672-8629.20220585

老年人用药风险管理原则和措施

朱愿超, 张亚同, 胡欣^*

北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京市药物临床风险与个体化应用评价重点实验室,北京医院,北京 100730

收稿日期:2022-09-30 出版日期:2023-09-15 发布日期:2023-09-14
通讯作者: ^*胡欣,男,主任药师,医院药学与老年安全用药。E-mail: yc4155@163.com
作者简介:朱愿超,女,硕士,副主任药师,老年药学及抗感染药物治疗。
基金资助:
中央高水平医院临床科研业务费（BJ-2022-173）; 国家重点研发计划（2020YFC2009001）

Principles and measures of medication risk management in the elderly

ZHU Yuanchao, ZHANG Yatong, HU Xin^*

Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application , Beijing Hospital, Beijing 100730, China

Received:2022-09-30 Online:2023-09-15 Published:2023-09-14

摘要/Abstract

摘要： 目的探讨老年人用药风险的原因,并提出风险管理原则和措施。方法从药动学特点、药效学特点、多重用药、用药依从性4个方面分析老年人用药风险高的原因,并阐述老年用药风险管理原则。结果根据老年人用药风险管理原则,建立老年多学科工作团队,进行老年综合评估管理实践,探索建立老年人用药风险的主动管理措施。结论基于老年人用药原则,积极探索主动用药风险管理措施是目前改善老年人多重用药问题的有效方法。

关键词: 老年人, 多重用药, 老年综合评估, 药品不良反应, 风险管理

Abstract: Objective To study the causes of medication risks in the elderly and recommend measures of management. Methods The risk factors for medication in the elderly were analyzed in terms of pharmacokinetics, pharmacodynamics, polypharmacy and poor medication compliance. The principles of risk management and control for the elderly were explained to ensure the medication safety. Results According to the principles of medication risk management for the elderly, a multidisciplinary geriatric work team was established for geriatric assessment. Active management and control strategies for drug risks among the elderly were formulated. Conclusion Active exploration of management and control measures against medication risks based on medication principles of the elderly is an effective solution to polypharmacy in the elderly.

Key words: elderly, polypharmacy, comprehensive assessment of the elderly, adverse drug reaction, risk management

中图分类号:

R994.11

朱愿超, 张亚同, 胡欣. 老年人用药风险管理原则和措施[J]. 中国药物警戒, 2023, 20(9): 1031-1034.

ZHU Yuanchao, ZHANG Yatong, HU Xin. Principles and measures of medication risk management in the elderly[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.

参考文献

[1] Ministry of Civil Affairs of China. Statistical Bulletin of Social Service Development in 2015[EB/OL]. (2016-07-11) [2022-09-26]. http://www.gov.cn/xinwen/2016-07/11/content_5090289.htm.
[2] National Bureau of Statistics of the People's Republic of China . Communiqué of the Seventh National Population Census (No. 5) [EB/OL]. (2021-05-11)(2022-11-30). http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
[3] FANG EF, SCHEIBY E-KNUDSEN M, JOHN HJ, et al. A research Agenda for aging in China the 21stcentury[J]. Ageing Res Rev, 2015, 24(PtB): 197-205.
[4] TINETTI ME, STUDENSKI SA.Comparative effectiveness research and patients with multiple chronic conditions[J]. N Engl J Med, 2011, 364(26): 2478-2481.
[5] World Health Organization. Medication safety in polypharmacy[EB/OL]. (2019-09-20)[2020-12-02]. https://apps.who.int/iris/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-eng.pdf?sequence=1&isAllowed=y.
[6] CAO F,WANG YB,XUE WG.Clinical multi-centers report of chronic diseases among elderly inpatients in China[J]. Chin J Mult Organ Dis Elderly,2018, 17(11): 801-808.
[7] ALHAWASSI TM, KRASS I, BAJOREK BV, et al.A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting[J]. Clin Interv Aging, 2014, 9: 2079-2086.
[8] BUTLER JM, BEGG EJ.Free drug metabolic clearance in elderly people[J]. Clin Pharmacokinet, 2008, 47(5): 297-321.
[9] CERRETA F, EICHLER HG, RASI G.Drug policy for an aging population-the European Medicine Agency's geriatric medicines strategy[J]. NEngl J Med, 2012, 367(21): 1972-1974.
[10] CHARLESWORTH CJ, SMIT E, LEE D, et al.Polypharmacy among adults aged 65 years and older in the United States: 1988-2010[J]. J Gerontol A Biol Sci Med Sc, 2015, 70(8): 989-995.
[11] JOHNELL K, KLARIN L.The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600, 000 elderly patients from the Swedish Prescribed Drug Register[J]. Drug Saf, 2007, 30(10): 911-918.
[12] World Health Organization.Adherence to long-term therapies:evidence for action[EB/OL]. (2003-01-01)[2022-10-02]. http://www.who.int/chp/knowledge/publications/adherence_report/en.2003.
[13] LAI XX, HUO XP, AN QZ, et al.Survey and analysis of status quo of polypharmacy in elderly patients[J]. Chinese Nursing Research(护理研究), 2016, 30(19): 2374-2378.
[14] SINO CG, SIETZEMA M, EGBERTS TC, et al.Medication management capacity in relation to cognition and self-management skills older people on polypharmacy[J]. J Nutr Health Aging, 2014, 18(1): 44-49
[15] ZHU JL, JIANG J, HUO Y.Effect of mobile health on improving adherence in cardiovascular disease patients[J]. Adv Cardiovasc Dis(心血管病学进展), 2017, 38(6): 635-639.
[16] HANLON JT, SCHMADER KE, SAMSA GP, et al.A method for assessing drug therapy appropriateness[J]. J Clin Epidemiol,1992,45(10): 1045-1051.
[17] By the 2019 American Geriatrics Society Beers Criteria^® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria^® for Potentially Inappropriate Medication Use in Older Adults the 2019 American Geriatrics Society Beers Criteria^® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria^® for Potentially Inappropriate Medication Use in Older Adults[J]. J Am Geriatr Soc, 2019, 67(4): 674-694.
[18] O'MAHONY D, O'SULLIVAN D, BYRNE S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2[J]. Age Ageing, 2015, 44(2): 213-218.
[19] Rational Drug Use Branch of China Association of Geriatric Research. Criteria of Potentially Inappropriate Medication for Older Adults in China[J]. Adverse Drug Reac Journal(药物不良反应杂志), 2018, 20(1): 2-8.
[20] YIN LX, ZHANG LH.Special Population Medication Guidance Series: Medication Guidance for the Elderly (特殊人群用药指导丛书老年人用药指导) [M]. Beijing: People's Health Publishing House, 2012.
[21] GHOSH P, DEWANJI A.Effect of reporting bias in the analysis of spontaneous reporting data[J]. Pharm Stat, 2015, 14(1): 20-25.
[22] WADMAN M.Experts call for active surveillance of drug safety[J]. Nature, 2007, 446( 7134) : 358-359.
[23] WANG D.Active surveillance of adverse drug reaction and its development trend[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(10): 600-602.
[24] CHEN C, XU YJ, GUO DH, et al.Advances in the application of computer technology for drug safety monitoring in medical institutions[J]. China Pharm acy(中国药房), 2014, 25(5): 461-464.
[25] BIAN Y, FENG JJ, LIN L.Monitoring methods for adverse drug reactions[J]. J Chin Res Hosp(中国研究型医院), 2019, 6(3): 46-49.
[26] ZHAO ZN, JIN PF, ZHAO F, et al.Establishment and application of the active surveillance program for PD-1/PD-L1 inhibitor-associated lung injury[J]. Adverse Drug Reac Journal(药物不良反应杂志), 2022, 24(2): 61-66.
[27] ZHU YC, WU WB, SHEN J, et al.clinical characteristics and risk factors of cefoperazone sodium sulbactam sodium induced coagulation disorders[J]. Chin Pharm J(中国药学杂志), 2022, 57(9): 741-746.
[28] CAI Z, YANG W, HE Y, et al.Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature[J]. Drug safety-case reports, 2016, 3(1):2.

老年人用药风险管理原则和措施

Principles and measures of medication risk management in the elderly

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.